NITROGLYCERIN tablet

Nazione: Stati Uniti

Lingua: inglese

Fonte: NLM (National Library of Medicine)

Principio attivo:

NITROGLYCERIN (UNII: G59M7S0WS3) (NITROGLYCERIN - UNII:G59M7S0WS3)

Commercializzato da:

Medical Purchasing Solutions, LLC

INN (Nome Internazionale):

NITROGLYCERIN

Composizione:

NITROGLYCERIN 0.4 mg

Via di somministrazione:

SUBLINGUAL

Tipo di ricetta:

PRESCRIPTION DRUG

Indicazioni terapeutiche:

Nitroglycerin sublingual tablets are indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease.  Nitroglycerin sublingual tablets are contraindicated in patients who are allergic to it.   Sublingual nitroglycerin therapy is contraindicated in patients with early myocardial infarction, severe anemia, increased intracranial pressure, and those with a known hypersensitivity to nitroglycerin.  Administration of nitroglycerin sublingual tablets are contraindicated in patients who are using a phosphodiesterase-5 (PDE-5) inhibitor (e.g., sildenafil citrate, tadalafil, vardenafil hydrochloride) since these compounds have been shown to potentiate the hypotensive effects of organic nitrates. Do not use nitroglycerin sublingual tablets in patients who are taking the soluble guanylate cyclase stimulator riociguat. Concomitant use can cause hypotension.

Dettagli prodotto:

Nitroglycerin sublingual tablets are supplied in 3 strengths (0.3 mg, 0.4 mg, and 0.6 mg) in bottles containing 100 tablets each, with color-coded labels, and in color-coded Patient Convenience Packages of 4 bottles of 25 tablets each.  0.3 mg sublingual tablets are white to off-white, modified rectangle shaped tablets debossed with "CL" on one side and "3" on the other side and are supplied in bottles of 100 tablets.   Bottle of 100 NDC 43598-435-01 0.4 mg sublingual tablets are white to off-white, modified rectangle shaped tablets debossed with "CL" on one side and "4" on the other side and are supplied in bottles of 25 and 100 tablets.   Bottle of 100 NDC 43598-436-01 Convenience Package NDC 43598-436-11 0.6 mg sublingual tablets are white to off-white, modified rectangle shaped tablets debossed with "CL" on one side and "6" on the other side and are supplied in bottles of 100 tablets.   Bottle of 100 NDC 43598-437-01 Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].   Rx only Manufactured by: Ingenus Pharmaceuticals NJ, LLC Fairfield, NJ 07004, USA Manufactured for: Dr. Reddy’s Laboratories Inc . Princeton, New Jersey 08540, USA Revised: 0217

Stato dell'autorizzazione:

Abbreviated New Drug Application

Scheda tecnica

NITROGLYCERIN- NITROGLYCERIN TABLET
MEDICAL PURCHASING SOLUTIONS, LLC
----------
NITROGLYCERIN SUBLINGUAL TABLETS USP
DESCRIPTION
Nitroglycerin is a stabilized sublingual compressed nitroglycerin
tablet that contains 0.3
mg, 0.4 mg, or 0.6 mg nitroglycerin USP; as well as calcium stearate
powder, colloidal
silicon dioxide, hydrogenated vegetable oil, lactose monohydrate, and
pregelatinized
starch.
Nitroglycerin, an organic nitrate, is a vasodilating agent. The
chemical name for
nitroglycerin is 1, 2, 3 propanetriol trinitrate and the chemical
structure is:
Molecular weight: 227.09
CLINICAL PHARMACOLOGY
The principal pharmacological action of nitroglycerin is relaxation of
vascular smooth
muscle. Although venous effects predominate, nitroglycerin produces,
in a dose-related
manner, dilation of both arterial and venous beds. Dilation of
postcapillary vessels,
including large veins, promotes peripheral pooling of blood, decreases
venous return to
the heart, and reduces left ventricular end-diastolic pressure
(preload). Nitroglycerin also
produces arteriolar relaxation, thereby reducing peripheral vascular
resistance and
arterial pressure (afterload), and dilates large epicardial coronary
arteries; however, the
extent to which this latter effect contributes to the relief of
exertional angina is unclear.
Therapeutic doses of nitroglycerin may reduce systolic, diastolic, and
mean arterial blood
pressure. Effective coronary perfusion pressure is usually maintained,
but can be
compromised if blood pressure falls excessively, or increased heart
rate decreases
diastolic filling time.
Elevated central venous and pulmonary capillary wedge pressures, and
pulmonary and
systemic vascular resistance are also reduced by nitroglycerin
therapy. Heart rate is
usually slightly increased, presumably due to a compensatory response
to the fall in
blood pressure. Cardiac index may be increased, decreased, or
unchanged. Myocardial
oxygen consumption or demand (as measured by the pressure-rate
product, tension-
time index, and stroke-work